Sleeping Beauty transposon-mediated transfection of retinal and iris pigment epithelial cells

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 8, 2012, Pages 4787-4796

  Johnen, Sandra ^a   Izsvák, Zsuzsanna ^b   Stöcker, Michael ^c   Harmening, Nina ^a   Salz, Anna Katharina ^a   Walter, Peter ^a   Thumann, Gabriele ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; PIGMENT EPITHELIUM DERIVED FACTOR; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL SELECTION; CONTROLLED STUDY; COW; ELECTROPORATION; FLOW CYTOMETRY; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IRIS; NONHUMAN; PIGMENT EPITHELIUM; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLEEPING BEAUTY TRANSPOSON; TRANSPOSON; WESTERN BLOTTING; ANIMAL; CATTLE; CELL CULTURE; CYTOLOGY; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; METABOLISM; METHODOLOGY; RETINA; RETINA MACULA DEGENERATION;

ANIMALS; BLOTTING, WESTERN; CATTLE; CELLS, CULTURED; DNA TRANSPOSABLE ELEMENTS; ELECTROPORATION; EYE PROTEINS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; IRIS; MACULAR DEGENERATION; NERVE GROWTH FACTORS; PIGMENT EPITHELIUM OF EYE; PROTEASE INHIBITORS; RETINA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERPINS; TRANSFECTION;

EID: 84866492042     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9951     Document Type: Article

References (58)

1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331:1480-1487.
2. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest. 1996;74:819-825.
3. Holekamp NM, Bouck N, Volpert O. Pigment epithelium derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol. 2002;134:220-227.
4. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
5. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58.
6. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145:249-256.
7. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
8. Pauleikhoff D, Scheider A, Wiedmann P, et al. Neovascular age related macular degeneration in Germany. Encroachment on the quality of life and the financial implications. Ophthalmologe. 2009;106:242-251.
9. Coleman HR, Chan CC, Ferris FL III, Chew EY. Age-related macular degeneration. Lancet. 2008;372:1835-1845.
10. Krishnan R, Goverdhan S, Lochhead J. Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization. Clin Experiment Ophthalmol. 2009;37:384-388.
11. Carneiro AM, Barthelmes D, Falcão MS, et al. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica. 2011;225:211-221.
12. Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res. 1991;53:411-414.
13. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium derived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245-248.
14. Duh EJ, Yang HS, Suzuma I, et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci. 2002;43:821-829.
15. Falk T, Zhang S, Sherman SJ. Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease. Neurosci Lett. 2009;458:49-52.
16. Filleur S, Volz K, Nelius T, et al. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res. 2005; 65:5144-5152.
17. Garcia M, Fernandez-Garcia NI, Rivas V, et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res. 2004;64:5632-5642.
18. Auricchio A, Behling KC, Maguire AM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther. 2002;6:490-494.
19. Mori K, Gehlbach P, Yamamoto S, et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2002;43: 1994-2000.
20. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neo vascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther. 2006;17:167-176.
21. Saishin Y, Silva RL, Saishin Y, et al. Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. Hum Gene Ther. 2005;16: 473-478.
22. Miyazaki M, Ikeda Y, Yonemitsu Y, et al. Pigment epithelium derived factor gene therapy targeting retinal ganglion cell injuries: neuroprotection against loss of function in two animal models. Hum Gene Ther. 2011;22:559-565.
23. Murakami Y, Ikeda Y, Yonemitsu Y, et al. Inhibition of choroidal neovascularization via brief subretinal exposure to a newly developed lentiviral vector pseudotyped with Sendai viral envelope proteins. Hum Gene Ther. 2010;21:199-209.
24. Lu Y, Song S. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc Natl Acad Sci US A.2009;106:17158-17162.
25. Hackett CS, Geurts AM, Hackett PB. Predicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy. Genome Biol. 2007;8 (Suppl 1):S12.
26. Stieger K, Colle MA, Dubreil L, et al. Subretinal delivery of recombinant AAV serotype 8 vector in dogs results in gene transfer to neurons in the brain. Mol Ther. 2008;16:916-923.
27. Thumann G. Nonviral gene therapy for age-related macular degeneration. Expert Rev Ophthalmol. 2011;6:81-93.
28. Mates L, Chuah MK, Belay E, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet. 2009;41:753-761.
29. Zayed H, Izsvák Z, Walisko O, Ivics Z. Development of hyperactive sleeping beauty transposon vectors by mutational analysis. Mol Ther. 2004;9:292-304.
30. Izsvák Z, Chuah MK, VandenDriessche T, Ivics Z. Efficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors. Methods. 2009;49:287-297.
31. Ivics Z, Izsvák Z. Nonviral gene delivery with the sleeping beauty transposon system. Hum Gene Ther. 2011;22:1043-1051.
32. Belur LR, Podetz-Pedersen KM, Sorenson BS, et al. Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System. Mol Cancer. 2011;10:14.
33. Wu A, Oh S, Ericson K, et al. Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma. Cancer Gene Ther. 2007;14:550-560.
34. Williams DA. Sleeping beauty vector system moves toward human trials in the United States. Mol Ther. 2008;16:1515-1516.
35. Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther. 2010;18: 674-683.
36. Kebriaei P, Huls H, Jena B, et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. 2012;23:444-450.
37. Stöcker M, Tur MK, Sasse S, Krüssmann A, Barth S, Engert A. Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif. 2003;28:211-219.
38. Cui Z, Geurts AM, Liu G, Kaufman CD, Hackett PB. Structure function analysis of the inverted terminal repeats of the sleeping beauty transposon. J Mol Biol. 2002;318:1221-1235.
39. Thumann G, Stöcker M, Maltusch C, et al. High efficiency onviral transfection of retinal and iris pigment epithelial cells with pigment epithelium-derived factor. Gene Ther. 2010;17: 181-189.
40. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high expression transfectants with a novel eukaryotic vector. Gene. 1991;108:193-199.
41. Baer M, Nilsen TW, Costigan C, Altman S. Structure and transcription of a human gene for H1 RNA, the RNA component of human RNase P. Nucleic Acids Res. 1990;18: 97-103.
42. Kolacsek O, Krizsik V, Schamberger A, et al. Reliable transgene independent method for determining Sleeping Beauty transposon copy numbers. Mob DNA. 2011;2:5.
43. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101-1108.
44. Grabundzija I, Irgang M, Mátés L, et al. Comparative analysis of transposable element vector systems in human cells. Mol Ther. 2010;18:1200-1209.
45. Johnen S, Kazanskaya O, Armogan N, et al. Endogenic regulation of proliferation and zinc transporters by pigment epithelial cells nonvirally transfected with PEDF. Invest Ophthalmol Vis Sci. 2011;52:5400-5407.
46. Hartman ZC, Black EP, Amalfitano A. Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. Virology. 2007;358:357-372.
47. Yoshioka Y, Abe T, Wakusawa R, et al. Recombinant AAV-transduced iris pigment epithelial cell transplantation may transfer vector to native RPE but suppress systemic dissemination. Invest Ophthalmol Vis Sci. 2006;47:745-752.
48. Ginn SL, Liao SH, Dane A, et al. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression. Mol Ther. 2010;18:965-976.
49. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118:3132-3142.
50. Dezawa M, Takano M, Negishi H, Mo X, Oshitari T, Sawada H. Gene transfer into retinal ganglion cells by in vivo electroporation: a new approach. Micron. 2002;33:1-6.
51. Kachi S, Oshima Y, Esumi N, et al. Nonviral ocular gene transfer. Gene Ther. 2005;12:843-851.
52. Ivics Z, Hackett PB, Plasterk RH, Izsvák Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 1997;91:501-510.
53. Krieg AM. Minding the Cs and Gs. Mol Ther. 2000;1:209-210.
54. Geurts AM, Yang Y, Clark KJ, et al. Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther. 2003;8:108-117.
55. Alexopoulou AN, Couchman JR, Whiteford JR. The CMV early enhancer/chicken beta actin (CAG) promoter can be used to drive transgene expression during the differentiation of murine embryonic stem cells into vascular progenitors. BMC Cell Biol. 2008;9:2.
56. Chung S, Andersson T, Sonntag KC, Björklund L, Isacson O, Kim KS. Analysis of different promoter systems for efficient transgene expression in mouse embryonic stem cell lines. Stem Cells. 2002;20:139-145.
57. Liew CG, Draper JS, Walsh J, Moore H, Andrews PW. Transient and stable transgene expression in human embryonic stem cells. Stem Cells. 2007;25:1521-1528.
58. Orban TI, Apati A, Németh A, et al. Applying a "double feature" promoter to identify cardiomyocytes differentiated from human embryonic stem cells following transposon-based gene delivery. Stem Cells. 2009;27:1077-1087.